TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02451150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan tablets
Study: NCT01568749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol Formulation 2
Description: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol formulation 3
Description: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol formulation 4
Description: paracetamol
Study: NCT04178109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen/tramadol (27mg/75mg)
Description: Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol hydrochloride
Description: Patients in group B received IV tramadol 75mg every 8h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Patients in group B received IV paracetamol 1g every 8h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrochloride 7.5 MG/ML
Description: 300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine Hydrochloride 7.5 MG/ML
Description: 300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride
Description: 10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine Hydrochloride
Description: 10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia
Study: NCT01717794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thunderbeat technology

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard bipolar electrosurgery
Study: NCT06420713

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal Bone Augmentation of Alveolar Ridge
Description: Elevation of the flap in the anterior region of atrophic maxilla to receive particulate autogenous bone mixed with deproteinized bovine bone graft (Group A) or Leukocyte-and-Platelet-Rich Fibrin (L-PRF) mixed with deproteinized bovine bone graft (Group B). In both groups, bone augmentations were covered with a collagen membrane stabilized with pins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Groups
Description: The patients underwent Guided Bone Regeneration (GBR) procedures for the reconstruction of atrophic edentulous alveolar ridges and were divided into two groups according to the proposed treatment:~Group A - GBR using a mixture of particulate autogenous bone graft and deproteinized bovine bone graft (Bio-Oss® Small; Geistlich AG, Wolhusen, Switzerland).~Group B - GBR using a mixture of deproteinized bovine bone graft (Bio-Oss® Small) and L-PRF + Liquid Fibrinogen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implants
Description: After 8 months of GBR healing, dental implants were placed in the grafted regions using guided surgery techniques.~Cone beam computed tomography (CBCT) scans were performed preoperatively, immediately after the surgical procedure, and after 8 months of follow-up to measure the linear and volumetric changes in the alveolar ridge. At the time of dental implant placement, after an 8-month period following the GBR procedures, bone biopsies were obtained from the grafted area for histological and micro-CT analysis.~The stability of the implants was assessed using resonance frequency analysis in the immediate postoperative period and at 6 months postoperatively.~After the 6-month period following dental implant placement, the patients were cleared for implant-supported prosthetic rehabilitation.
Study: NCT01103219

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition
Description: The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
Study: NCT01552304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Study: NCT03109886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milciclib maleate
Description: 100 mg/day once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.
Study: NCT01990937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: 5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
Study: NCT01413113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131
Description: Given IM
Study: NCT02712411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1402
Study: NCT02076919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHA510 Ophthalmic Suspension
Description: Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHA510 Ophthalmic Suspension
Description: Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LHA510 Vehicle
Description: Inactive ingredients used for masking purposes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LHA510 Vehicle
Description: Inactive ingredients used for masking purposes
Study: NCT02786771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse headband
Study: NCT03899480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Natural Killer (NK) Cells
Description: infusion with N-803 activated NK cells
Study: NCT01977612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-0 monofilament suture
Description: Skin closure using 4-0 monofilament suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stainless steel staples
Description: Skin closure using stainless steel staples.
Study: NCT04628286

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Laser
Description: Sham Laser in plantar fascia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Induction
Description: Myofascial Induction in plantar fascia
Study: NCT03072121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: 1 tablet two times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg two times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg two times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.
Study: NCT02071979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Wound Care
Description: Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
Study: NCT01944410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: injection of PRP to traumatic bone cyst defect
Study: NCT04120051

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented canola-seaweed
Description: A daily sachet with 5 gram FCS-granulate for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily sachet with 5 gram rye cereal for 6 weeks
Study: NCT02516644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: 12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: 12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
Study: NCT02599844

Intervention type: DRUG
Intervention: Iodohippurate
Description: An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)

Intervention type: DRUG
Intervention: Iodohippurate
Description: An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)

Intervention type: PROCEDURE
Intervention: 24 hour ambulatory Blood Pressure
Description: Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.

Intervention type: PROCEDURE
Intervention: 24 hour ambulatory Blood Pressure
Description: Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.

Intervention type: PROCEDURE
Intervention: Peripheral Arterial Tonometry
Description: The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.

Intervention type: PROCEDURE
Intervention: Peripheral Arterial Tonometry
Description: The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.

Intervention type: PROCEDURE
Intervention: Pulse Wave Velocity
Description: Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.

Intervention type: PROCEDURE
Intervention: Pulse Wave Velocity
Description: Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.

Intervention type: DRUG
Intervention: Gadolinium
Description: Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.

Intervention type: DRUG
Intervention: Gadolinium
Description: Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
Study: NCT04128436

Intervention type: OTHER
Group type: OTHER
Intervention: Taking blood samples for analyzing progesterone levels
Description: As part of standard in vitro fertilization treatment, Crinone gel will be used starting the next morning following the oocyte pick-up (OPU) as a luteal phase support. On the trigger day, on the day OPU+2/3 (early luteal phase) and on the embryo transfer day (OPU+5, mid luteal phase) blood samples will be taken from patients for evaluating the progesterone levels. Blood samples will be collected at the 6th hour following the morning dose of vaginal progesterone gel. No other intervention will be done to the patients.
Study: NCT03311568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound for microcirculatory assessment
Description: Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface.
Study: NCT00902044

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous HER2-specific T cells
Description: Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous HER2-specific T cells
Description: Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
Study: NCT03311568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound for microcirculatory assessment
Description: Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound for microcirculatory assessment
Description: Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound for microcirculatory assessment
Description: Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface.
Study: NCT04672772

Intervention type: DRUG
Intervention: Cetuximab
Description: Weekly cetuximab at starting dose, that could be switched to biweekly

Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel at starting dose of 80 mg/m2
Study: NCT04505813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEXI-002 T Cells
Description: The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEXI-002 T Cells
Description: The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.
Study: NCT01672619

Intervention type: PROCEDURE
Intervention: dynamic craniotomy
Description: Surgical technique of craniotomy spiral without detachment of dura mater
Study: NCT02241668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3'-Deoxy-3'-18f-Fluorothymidine
Description: 3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
Study: NCT00130819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-based substance abuse treatment with buprenorphine
Description: Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management and referred substance abuse treatment
Description: Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
Study: NCT03709628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB8018 (First-in-class FimH blocker)
Description: Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker~• In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13.
Study: NCT00361517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Galactomannan antigen monitoring, Aspergillus PCR
Description: There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draws
Description: Blood is drawn for monitoring of Galactomannan antigen in the blood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draws for GM monitoring
Description: blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin-B deoxycholate
Description: 1-1.5mg/kg, i.v, once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test
Description: Blood will be tested twice a week for the presence of Galactomannan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
Study: NCT00357396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft versus host disease prophylaxis/therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT02496793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-facilitated community support group
Description: Support groups were composed of up to 20 women from community. Peer facilitator facilitated a total of 6 groups of a maximum of 20 women each. Women were exposed to 8 two hour sessions. Facilitators gave activities in support of MCH/PMTCT. Group met twice a month for four months. The support group meetings took place in the community at a convenient location for those attending (e.g. village meeting point, churches, schools or individual households). With local support through community leaders, the intervention involved trained peer facilitators working with pregnant and post-partum women to form ANC and PNC support groups through which they will present information on general maternal and child health and PMTCT specific topics using participatory learning and problem-solving approaches.
Study: NCT00487578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naratriptan HCl
Description: naratriptan 2.5mg tablet bid x 30 days OR matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naratriptan HCl
Description: naratriptan 2.5mg tablet bid x 30 days OR matching placebo
Study: NCT02030028

Intervention type: DRUG
Group type: OTHER
Intervention: ACTHAR gel
Description: Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
Study: NCT02231255

Intervention type: DRUG
Intervention: Sifrol®
Study: NCT01947049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Influenza Testing with Xpert Flu
Description: Participants with recieve rapid influenza testing with Xpert Flu
Study: NCT04484402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution